SynT Generation, validation and use of a synthetic reporter of CAR T cell products function and dysfunction
- Coordinator
- Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc), Germany
- Runs
- 1 March 2024 to 31 August 2025
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101158338
What the project is doing
In the project's own words, from its summary on CORDIS.
Cell-based immunotherapy, particularly adoptive cell transfer (ACT) using engineered T cells, holds great promise as a therapeutic strategy for cancer treatment. However, challenges such as the manufacturing process, excessive antigen exposure, and the hostile tumor microenvironment often lead to dysfunctional T cell products, limiting their effectiveness in treating both blood cancers and solid tumors. We propose a novel tool to define in vitro conditions to enhance T cell product fitness through the development of a synthetic reporter system for detecting T cell dysfunction states, referred to as SynT.
This innovative system will incorporate a dual synthetic locus control region (sLCR) reporter, with one sLCR reporter indicating T cells in a potent ""serial killer"" mode and another sLCR reporter representing T cell dysfunction. By using SynT, we aim to screen for external signaling and pharmacological modulators that can enrich and reverse the dysfunctional state in CAR T cells. we will generate and validate a synthetic reporter of CAR T cell products function and dysfunction, and produce a media supplement that promotes ACT products functions.""
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc) | Berlin | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI